Muscle Wasting in Hemodialysis Patient

Study of Muscle Wasting Mechanisms and Biomarkers in Hemodialysis Patient

NCT03583177•University Hospital, Clermont-Ferrand

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Muscle Atrophy in Lung Cancer and Hemodialysed Patients

Interventions

No intervention

Locations

France

Locations (1)

CHU de Clermont-Ferrand

Clermont-Ferrand, Auvergne, France

Key Dates

Start Date

July 1, 2009

Primary Completion Date

July 31, 2013

Completion Date

June 28, 2018

Last Updated

July 12, 2018

Sponsors

Lead Sponsor

University Hospital, Clermont-Ferrand

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 12, 2018Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions